Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Neuropharmacology. 2016 Jun 5;112(Pt A):150–163. doi: 10.1016/j.neuropharm.2016.06.005

Figure 6.

Figure 6

Ambulatory (top panel), non-ambulatory (middle panel) and vertical (bottom panel) activity measured over the-two hour test period during the sensitization phase after a systemic injection of amphetamine from the group pre-exposed to the vehicle (VEH, n=14), D-Tyr[11]Neurotensin (NT, n=16), Ro04-5595 (200 or 1200 pmol) with NT (Ro200+NT, n=7; Ro1200+NT, n=7) and Ro04-5595 alone (Ro200, n=6; Ro1200, n=7). Each bar represents the group mean ± s.e.m. Stars indicate a statistically significant difference with VEH (*p < 0.05; **p < 0.01; ***p < 0.001).

HHS Vulnerability Disclosure